Tumor News and Research

RSS

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

Pannexin1 protein may play an important role in mechanics of tumors

By studying tumor cell behavior in a novel "scaffold-free" 3-D system, researchers have determined that the protein Pannexin1 may play an important biomechanical role in binding tissues together, an effect that is lost in cancerous cells.

31 Jan 2012

Psychosocial interventions can reduce cancer patients' pain severity

Researchers at Moffitt Cancer Center, who teamed with colleagues at five universities around the United States, analyzed past studies of cancer-related pain reduction and found that psychosocial interventions can have a beneficial effect on cancer patients' pain severity. They also found that certain psychosocial interventions provide better pain management and are effective in reducing the degree to which pain related to cancer and its treatment interferes with patients' lives.

31 Jan 2012

Researchers decipher genetic material of 48 pediatric glioblastomas

Glioblastomas grow extremely aggressively into healthy brain tissue and, moreover, are highly resistant to radiation therapy and chemotherapy. Therefore, they are regarded as the most malignant type of brain tumor. Currently available treatment methods are frequently not very effective against this type of cancer. Glioblastoma can affect people of all ages, but is less common in children than in adults.

31 Jan 2012

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

Applied Spectral Imaging (ASI) announced today that ASI's GenASIs Scan & Analysis, SpotScan used for the detection of chromosomal aberrations in bladder cancer has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

30 Jan 2012

Researchers identify two genetic mutations responsible for brain cancer in children

An international research team led by the Research Institute of the McGill University Health Centre (RI MUHC) has made a major genetic breakthrough that could change the way pediatric cancers are treated in the future.

30 Jan 2012

Helios Berlin Buch acquires Mobetron for Intra-Operative Electron Radiation Therapy

IntraOp Medical Corporation today announced that Helios Berlin Buch became the fourth German hospital and the nineteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

30 Jan 2012

First evidence links cancer to mutations in genes involved in DNA organization

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization

30 Jan 2012

Inlyta receives FDA approval for treatment of advanced kidney cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

30 Jan 2012

New mechanism of drug release using 3D superhydrophobic materials

According to a recent study, there is a new mechanism of drug release using 3D superhydrophobic materials that utilizes air as a removable barrier to control the rate at which drug is released.

30 Jan 2012

Researchers develop new MRS technique to diagnose brain tumors

Researchers at UT Southwestern Medical Center have developed what they believe to be the first clinical application of a new imaging technique to diagnose brain tumors.

30 Jan 2012

Researchers identify possible cause for loss of tumor suppressor genes

Researchers at Queen's University in Kingston, Canada have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.

27 Jan 2012

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

BioReference Laboratories, Inc. and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH) is introducing its groundbreaking solid tumor genotype test.

27 Jan 2012

Scientists connect two signature characteristics of pancreatic cancer

Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

27 Jan 2012

UCSF team develops methods that may help predict brain tumor recurrence

After people with low-grade glioma, a type of brain cancer, undergo neurosurgery to remove the tumors, they face variable odds of survival - depending largely on how rapidly the cancer recurs. Even though their doctors monitor the tumor closely with sophisticated imaging, it is difficult to determine with certainty whether cancer has returned in a more malignant state that requires aggressive treatment.

25 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Novel detection of ovarian cancer in early stages

Ovarian cancer is often detected at a late stage and it is the leading cause of death due to gynecological cancers, and the sixth leading cause of cancer death in women. According to latest discovery by researchers at Sydney’s Garvan Institute there may be a way this killer cancer is detected earlier.

24 Jan 2012

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012